ArticleToxins2015
Increased circulating levels of vitamin D binding protein in MS patients.
Article in Toxins, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 44 citations in OpenAlex.
- Vitamin D binding protein induces skeletal muscle atrophy and contributes to cancer-associated muscle wasting independently of vitamin D status in preclinical models.Nature communications · 2026Article
- Proteomic analysis reveals candidate molecules to mediate cortical pathology and identify possible biomarkers in an animal model of multiple sclerosis.Frontiers in immunology · 2025Article
- Potential pathogenic and protective genotypes and phenotypes of vitamin D binding protein in multiple sclerosis.Frontiers in neurology · 2025Article
- Combination protein biomarkers predict multiple sclerosis diagnosis and outcomes.Journal of neuroinflammation · 2024Article
- Association of Blood Levels of Vitamin D and Its Binding Protein with Clinical Phenotypes of Multiple Sclerosis.Biomedicines · 2023Article
- Free vitamin DEuropean journal of neurology · 2022Article
- Reduction in circulating vitamin D binding protein in patients with multiple sclerosis.BMC neurology · 2021Article
- Vitamin D status and disability among patients with multiple sclerosis: a systematic review and meta-analysis.AIMS neuroscience · 2021Review
- Drugs for Multiple Sclerosis Activate Natural Killer Cells: Do They Protect Against COVID-19 Infection?Infection and drug resistance · 2020Review
- Article
- Review
- A review on potential roles of vitamins in incidence, progression, and improvement of multiple sclerosis.eNeurologicalSci · 2018Review
- Vitamin D and Neurological Diseases: An Endocrine View.International journal of molecular sciences · 2017Review
- VITAMIN D BINDING PROTEIN AND 25-HYDROXYVITAMIN D LEVELS: EMERGING CLINICAL APPLICATIONS.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2017Review
- Association of vitamin D status and clinical and radiological outcomes in a treated MS population in Poland.Brain and behavior · 2017Article
- Investigating causality in the association between 25(OH)D and schizophrenia.Scientific reports · 2016Article
- Iranian consensus on use of vitamin D in patients with multiple sclerosis.BMC neurology · 2016Review
- Anti-inflammatory nutritional intervention in patients with relapsing-remitting and primary-progressive multiple sclerosis: A pilot study.Experimental biology and medicine (Maywood, N.J.) · 2016Article
- Remission of Severe Myasthenia Gravis After Massive-Dose Vitamin D Treatment.The American journal of case reports · 2016Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vitamin D (vitD) low status is currently considered a main environmental factor in multiple sclerosis (MS) etiology and pathogenesis. VitD and its metabolites are highly hydrophobic and circulate mostly bound to the vitamin D binding protein (DBP) and with lower affinity to albumin, while less than 1% are in a free form. The aim of this study was to investigate whether the circulating levels of either of the two vitD plasma carriers and/or their relationship are altered in MS. We measured DBP and albumin plasma levels in 28 MS patients and 24 healthy controls. MS patients were found to have higher DBP levels than healthy subjects. Concomitant interferon beta therapy did not influence DBP concentration, and the difference with the control group was significant in both females and males. No significant correlation between DBP and albumin levels was observed either in healthy controls or in patients. These observations suggest the involvement of DBP in the patho-physiology of MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.